1099 Stock Overview
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Sinopharm Group Co. Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$21.45 |
52 Week High | HK$23.65 |
52 Week Low | HK$16.02 |
Beta | 0.85 |
1 Month Change | 4.38% |
3 Month Change | 25.00% |
1 Year Change | 12.30% |
3 Year Change | 28.75% |
5 Year Change | -24.34% |
Change since IPO | 15.82% |
Recent News & Updates
At HK$20.45, Is It Time To Put Sinopharm Group Co. Ltd. (HKG:1099) On Your Watch List?
Nov 26Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business
Nov 06Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04Recent updates
At HK$20.45, Is It Time To Put Sinopharm Group Co. Ltd. (HKG:1099) On Your Watch List?
Nov 26Sinopharm Group's (HKG:1099) Returns On Capital Not Reflecting Well On The Business
Nov 06Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Shareholder Returns
1099 | HK Healthcare | HK Market | |
---|---|---|---|
7D | -2.3% | -1.3% | -0.5% |
1Y | 12.3% | -17.8% | 19.9% |
Return vs Industry: 1099 exceeded the Hong Kong Healthcare industry which returned -17.8% over the past year.
Return vs Market: 1099 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
1099 volatility | |
---|---|
1099 Average Weekly Movement | 6.0% |
Healthcare Industry Average Movement | 8.3% |
Market Average Movement | 8.8% |
10% most volatile stocks in HK Market | 18.6% |
10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 1099 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1099's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 113,635 | Wanyong Lian | www.sinopharmgroup.com.cn |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.
Sinopharm Group Co. Ltd. Fundamentals Summary
1099 fundamental statistics | |
---|---|
Market cap | HK$66.94b |
Earnings (TTM) | HK$9.22b |
Revenue (TTM) | HK$629.15b |
7.3x
P/E Ratio0.1x
P/S RatioIs 1099 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1099 income statement (TTM) | |
---|---|
Revenue | CN¥590.35b |
Cost of Revenue | CN¥543.16b |
Gross Profit | CN¥47.18b |
Other Expenses | CN¥38.53b |
Earnings | CN¥8.65b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 2.77 |
Gross Margin | 7.99% |
Net Profit Margin | 1.47% |
Debt/Equity Ratio | 78.1% |
How did 1099 perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 22:57 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sinopharm Group Co. Ltd. is covered by 44 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jason Mann | Barclays |
Derrick Sun | BNP Paribas Securities (Asia) |
Bo Li | BofA Global Research |